PHARMACOLOGY
Oct 18, 2023
6 Min Read
Immunotherapy in Stage IV Renal Cell Carcinoma
Evaluating the five-year survivability rates of combination checkpoint inhibitors versus traditional TKI monotherapies in clinical practice.
Dr. Michael Vane
bookmark